all possibilities that come with an IJV‚ it could lead to potential losses. Eli Lilly Ranbaxy is an example of a joint venture that was pursued with the right strategy‚ which was a result due to a changing US pharmaceutical market and a rapidly expanding India market. The two companies in this IJV were both significant players within their home countries‚ Eli Lilly and Company in the US and Ranbaxy Laboratories Limited from India. When the possibility of establishing a joint venture was approached
Premium Joint venture Generic drug Ranbaxy Laboratories
I would like to especially thank my Professors- Mr. Y G Chouksey‚ my oldest friend and source of inspiration in the institute; Mr. S Jayaraman How can I forget to thank Mr. Vimlendu K Singh (GM-API Business‚ Ranbaxy Laboratories Ltd)‚ due to whom my dream of working with Ranbaxy came to a reality. My sincere thanks to him for all his support and efforts to make me comfortable in the organization. And lastly my thank to the one who is my most consistent friend. He never speaks to me‚ yet
Premium Generic drug Ranbaxy Laboratories Pharmaceutical industry
ELI LILLY IN INDIA RETHINKING THE JOINT VENTURE Kishore – 01 STRATEGY Abhay Abhishek Kunal – 05 Anil Kumar Jadli – 11 J.Harish – 25 Khushal Malik – 28 Sharad Singh – 49 PHARMACEUTICAL INDUSTRY – Global Trend • • • • Mainly concentrated in the United States‚ Europe‚ and Japan Developing a drug from discovery to launch took 10 to 12 years. Cost of development of drug is between $500-$800 million. Drugs were strictly controlled by government agencies: o Food and Drug Administration (FDA) – USA‚
Premium Generic drug Pharmaceutical industry Ranbaxy Laboratories
RANBAXY LABORATORIES LTD RESEARCH EQUITY RESEARCH July 10‚ 2008 RESULTS REVIEW Share Data Market Cap Price BSE Sensex Reuters Bloomberg Avg. Volume (52 Week) 52-Week High/Low Shares Outstanding Valuation Ratios (Consolidated) Year to 31 December 2008E EPS (Rs.) 14.7 EPS Growth (%) 27.8% PER (x) 36.6x EV/ Sales (x) 3.2x 19.2x EV/ EBITDA (x) Shareholding Pattern (%) Promoters FIIs Institutions Public & Others Relative Performance 700 600 500 400 300 200 Jul-07 Aug-07 Sep-07 Oct-07 Nov-07 Dec-07
Premium Ranbaxy Laboratories Revenue Generic drug
Tata Motors The Indian Automobile industry The automotive sector is one of the core industries of the Indian economy‚ Continuous economic liberalization over the years by the government of India has resulted in making India as one of the prime business destination for many global automotive players. The automotive sector in India is growing at around 18 per cent per annum. The cumulative annual growth rate of production of the automotive industry from the year 2000-2001 to 2005-2006 was 17 per
Premium Tata Motors Automotive industry Ranbaxy Laboratories
------------------------------------------------- Fundamental Analysis Fundamental analysis is a technique that attempts to determine a security’s value by focusing on underlying factors that affect a company ’s actual business and its future prospects. On a broader scope‚ you can perform fundamental analysis on industries or the economy as a whole. The term simply refers to the analysis of the economic well-being of a financial entity as opposed to only its price movements. Fundamental analysis
Premium Generic drug Pharmaceutical industry Financial ratios
Industry overview Pharmaceutical sector is an important industry of any modern day economic power. Pharmaceutical industry in India has a very humble past. After independence‚ development of pharmaceutical industry was one of the top agenda of government along with steel and manufacturing industry. The market was protected against competition for a long period of time by giving incentives to small firms‚ license-raj etc. Today the Indian pharmaceutical industry is the front-runner science-based
Premium Pharmaceutical industry Generic drug Food and Drug Administration
Interview Process At Ranbaxy R.P. Report Compiled By: Aditi Apoorva Nayan Swati Shivani Under the Guidance of Prof. N.N.Akhouri Ranbaxy Laboratories Limited: Ranbaxy is one of India ’s largest pharmaceutical companies. Incorporated in 1961‚ Ranbaxy exports its products to 125 countries with ground operations in 46 and manufacturing facilities in seven countries. The company went public in 1973‚ and Japanese company Daiichi Sankyo gained majority control in 2008. Milestones
Premium Ranbaxy Laboratories Generic drug Recruitment
SUN Pharma Company was established as a partnership firm by Dilip Sanghvi & his family to manufacture pharmaceutical formulations at Vapi‚ Gujarat. The Company specializes in selected therapeutic segment to psychiatry‚ cardiology‚ neurology‚ gastroenterology‚ orthopedics‚ ophthalmology nephrology and diabetology. It also makes Active Pharmaceutical Ingredients such as warfarin‚ carbamazepine‚ etodolac ‚ clorazepate‚ anticancers‚ steroids‚ peptides‚ sex hormones‚ and controlled substances. It is
Premium Pharmacology Pharmacology Ranbaxy Laboratories
take. Ranbaxy Laboratories wants to be bought out‚ but Eli Lilly is worried of the financial implications of such move. There were two pharmaceutical companies that were looking for ways to expand globally to position themselves in a competitive advantage from their competitors. One was located in the United States‚ which was Eli Lilly and Company and the other one was located in India‚ which was Ranbaxy Laboratories. Research and development was crucial to Lilly’s long-term success. Ranbaxy Laboratories
Premium Generic drug Pharmaceutical industry Clinical trial